|Nabilone *||Antiemetic||Film-coated tablets||1 mg|
|Ondansetron||Nausea & vomiting||Film-coated tablets||4 and 8 mg|
|Ondansetron||Nausea & vomiting||Orodispersable tablets||4 and 8 mg|
|Otilonium bromide||Irritable bowel syndrome||Film-coated tablets||40 mg|
|Paracetamol / Tramadol||Analgesic||Effervescent tablets||325/37.5 mg|
|Prasugrel Base||Prophylaxis and therapy of thrombosis||Film-coated tablets||5 and 10 mg|
|Rivaroxaban||Thrombosis, stroke||Film-coated tablets||10, 15 and 20 mg|
|Rizatriptan||Migraine||Orodispersable tablets||5 and 10 mg|
|Solifenacin||Overactive bladder, urinary incontinence||Film-coated tablets||5 and 10 mg|
|Valsartan||Hypertension||Film-coated tablets||40, 80, 160 and 320 mg|
|Valsartan + HCTZ||Hypertension||Film-coated tablets||80/12.5, 160/12.5/ 320/12.5, 160/25 and 320/25 mg|
|Zolmitriptan||Migraine||Orodispersable tablets||2.5 and 5 mg|
[*] Differentiated product
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.